NKCL Bio Group Inc. won the grand prize in the NK cell therapy category at the 17th ‘Korea Health Industry Awards’ in 2023

The Korea Health Industry Award, which provides an opportunity to spread awareness about the importance of the health industry, raises its status, and boosts morale in the health industry, by discovering and awarding companies that have made great contributions to the development of the health industry in Korea every year. It was designed by the 'Health Industry CEO Meeting' and celebrated its 17th this year.

The organizers announced that among the candidates who contributed to the development of the health industry last year, the honor of the award went to the final companies, institutions, and individuals who passed the approval of the head of each institution and the post-examination.

In June of this year, NKCL Bio Group succeeded in miniaturizing the NK cell automatic culturing system grafted with AI and launched the RK-NKTM ACS, an automatic culturing machine for one person, and is accelerating the overseas expansion of K-Bio.

[Source] Business Korea

http://www.businesskorea.co.kr/news/articleView.html?idxno=117611